NEW INDICATION
ERLEADA® (apalutamide) is now approved for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
Tablets shown are not actual size.
The recommended dose of ERLEADA® is 240 mg (four 60 mg tablets) administered orally once daily 1
Patients should also receive a GnRH analog concurrently or should have had a bilateral orchiectomy.1
No need for co-administration of a corticosteroid.1
Can be taken with or without food. Tablets should be swallowed whole.1
No initial dose adjustments for ERLEADA® are necessary for renal or hepatic impairment.*1
Dose Modifications
If a patient experiences a ≥Grade 3 toxicity or an intolerable side effect, hold dosing until symptoms improve to ≤Grade 1 or original grade, and then resume at the same dose or a reduced dose (180 mg or 120 mg), if warranted.1
*ERLEADA® has not been evaluated in patients with severe renal or hepatic impairment.
GnRH = gonadotropin-releasing hormone.
Reference
1. ERLEADA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.